Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for SIP receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.
Type:
Application
Filed:
September 26, 2023
Publication date:
May 9, 2024
Applicant:
NEXTGEN BIOSCIENCE CO., LTD.
Inventors:
Bong Yong LEE, Yang Hae PARK, Eun Jeong KIM
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating alopecia areata acting as a functional antagonist for S1P receptor's subtypes S1PR1 and S1PR4, and more particularly, relates to a pharmaceutical composition containing as an active ingredient a sphingolipid compound acting as a functional antagonist for S1PR1 and S1PR4, does not cause cardiovascular side effects, and is effective in preventing or treating alopecia areata.
Type:
Grant
Filed:
September 26, 2023
Date of Patent:
April 16, 2024
Assignee:
NEXTGEN BIOSCIENCE CO., LTD.
Inventors:
Bong Yong Lee, Yang Hae Park, Eun Jeong Kim
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease acting as a functional antagonist for S1PR1 and S1PR4 of S1P receptors, and more specifically, to a pharmaceutical composition including, as an active ingredient, a sphingolipid compound which does not cause cardiovascular side effects by acting as a functional antagonist for S1PR1 and S1PR4 and has an effect of preventing or treating inflammatory bowel disease.
Type:
Application
Filed:
September 28, 2023
Publication date:
February 8, 2024
Applicant:
NEXTGEN BIOSCIENCE CO., LTD.
Inventors:
Bong Yong LEE, Yang Hae PARK, Eun Jeong KIM